Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.73 |
| ▸ | P4HB | P07237 | 6/20 | 0.73 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.73 |
| ▸ | MAOA | P21397 | 4/20 | 0.73 |
| ▸ | XDH | P47989 | 4/20 | 0.73 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.73 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | CA12 | O43570 | 2/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | CA4 | P22748 | 2/20 | 0.73 |
| ▸ | CA7 | P43166 | 2/20 | 0.73 |
| ▸ | GAA | P10253 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | POLB | P06746 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALPI | P09923 | 2/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510346 | 1.00 | KDM4E (0.73) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| SCHEMBL7601750 | 1.00 | KDM4E (0.73) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| SCHEMBL2510457 | 0.93 | NQO2 (0.72) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| SCHEMBL180904 | 0.88 | KDM4E (0.69) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| Acetone SCHEMBL11411008 | 0.88 | AKR1B1 (0.70) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| SCHEMBL25414144 | 0.87 | P4HB (0.83) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| SCHEMBL8374228 | 0.86 | KDM4E (0.71) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| SCHEMBL925803 | 0.86 | KDM4E (0.71) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| SCHEMBL21408655 | 0.86 | AKR1B1 (0.74) | KDM4EP4HBAKR1B1EPHX2MAOA | |
| SCHEMBL24608 | 0.86 | AKR1B1 (0.74) | KDM4EP4HBAKR1B1EPHX2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101791-A1 | POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200093851-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10314853-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180235987-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180147222-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9901595-B2 | Glycan therapeutics for reducing blood ammonia | KALEIDO BIOSCIENCES, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9757403-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170246201-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170151268-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151269-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |